PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 144 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 0.54 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $22,000 | +10.0% | 4,729 | 0.0% | 0.01% | -12.5% |
| Q4 2018 | $20,000 | -23.1% | 4,729 | +10.5% | 0.01% | -27.3% |
| Q3 2018 | $26,000 | -25.7% | 4,279 | -1.2% | 0.01% | -26.7% |
| Q2 2018 | $35,000 | +12.9% | 4,329 | 0.0% | 0.02% | +15.4% |
| Q1 2018 | $31,000 | +72.2% | 4,329 | +50.4% | 0.01% | +62.5% |
| Q4 2017 | $18,000 | -14.3% | 2,878 | +0.9% | 0.01% | -20.0% |
| Q3 2017 | $21,000 | +250.0% | 2,852 | +226.7% | 0.01% | +233.3% |
| Q2 2017 | $6,000 | -25.0% | 873 | -0.3% | 0.00% | -25.0% |
| Q1 2017 | $8,000 | 0.0% | 876 | -4.6% | 0.00% | 0.0% |
| Q4 2016 | $8,000 | – | 918 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 1,583,925 | $8,007,000 | 1.48% |
| Phocas Financial Corp. | 1,022,708 | $5,169,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,776,490 | $8,980,000 | 0.32% |
| FARALLON CAPITAL MANAGEMENT LLC | 7,350,000 | $37,154,000 | 0.28% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 716,880 | $3,624,000 | 0.23% |
| J. Goldman & Co LP | 499,698 | $2,526,000 | 0.19% |
| PINNACLE ASSOCIATES LTD | 1,257,098 | $6,355,000 | 0.15% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $19,957,000 | 0.14% |
| EAGLE ASSET MANAGEMENT INC | 4,504,094 | $22,768,000 | 0.12% |
| Worth Venture Partners, LLC | 32,956 | $167,000 | 0.10% |